Print this page
melanoma
-
Cutaneous Oncology Clinical Database and Biospecimen Bank
Protocol: 002233Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma.
Protocol: 011909Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma.
Protocol: 012207Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Any Site -
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.
Protocol: 012314Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma.
Protocol: 012320Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects with Advanced or Metastatic PD-L1 High [TPS>50%J Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-Lung08) - Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-Line Treatment of Subjects with Advanced or Metastatic NSCLC without Actionable Genomic Alterations.
Protocol: 032211Applicable Disease Sites: Lung
-
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer.
Protocol: 032309Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing.
Protocol: 032402Principal Investigator:
- Taha Mur
Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
An Adjuvant Endocrine-Based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer.
Protocol: 042312Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease.
Protocol: 042404Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Any Site
Liver
Other Digestive Organ -
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and
Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Protocol: 052410Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum